At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CTIC CTI BIOPHARMA
Halted 11-22 16:00:00 EST
9.09
+0.00
0.00%
High9.09
Low9.09
Vol0.00
Open9.09
D1 Closing9.09
Amplitude0.00%
Mkt Cap1.20B
Tradable Cap908.00M
Total Shares131.88M
T/O0.00
T/O Rate0.00%
Tradable Shares99.89M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
มหาวิทยาลัยแห่งชาติสิงคโปร์ร่วมกับสถาบันดีคิว เปิดตัวโครงการ "Living Well Dig
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.